Expert: Bluebird Bio Is 'One Of The Better Stories In Biotech'
TheStreet Senior Columnist Adam Feuerstein discussed bluebird bio Inc (NASDAQ: BLUE) on the show and said that it was “one of the better stories in biotech over the last year.”
Feuerstein said that bluebird was at the forefront of a group of companies that are working on gene therapy for diseases as the science and technology evolved from early stages.
Gene therapy, unlike traditional drugs, can potentially cure disease rather than just treat symptoms, according to Feuerstein.
Data was expected from the company this year on its sickle cell therapy which would follow December’s strong results from its beta thalassemia therapy, which Feuerstein said was exciting to investors.
Bluebird bio recently traded at $133.29, down 0.48 percent
Check out the full interview below. Feuerstein comes in at about the one-hour mark:
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.